Literature DB >> 20334914

Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.

Hadrian Szpurka1, Anna M Jankowska, Hideki Makishima, Juraj Bodo, Nelli Bejanyan, Eric D Hsi, Mikkael A Sekeres, Jaroslaw P Maciejewski.   

Abstract

While a majority of patients with refractory anemia with ring sideroblasts and thrombocytosis harbor JAK2V617F and rarely MPLW515L, JAK2/MPL-negative cases constitute a diagnostic problem. 23 RARS-T cases were investigated applying immunohistochemical phospho-STAT5, sequencing and SNP-A-based karyotyping. Based on the association of TET2/ASXL1 mutations with MDS/MPN we studied molecular pattern of these genes. Two patients harbored ASXL1 and another 2 TET2 mutations. Phospho-STAT5 activation was present in one mutated TET2 and ASXL1 case. JAK2V617F/MPLW515L mutations were absent in TET2/ASXL1 mutants, indicating that similar clinical phenotype can be produced by various MPN-associated mutations and that additional unifying lesions may be present in RARS-T. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334914      PMCID: PMC2953471          DOI: 10.1016/j.leukres.2010.02.033

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  29 in total

1.  Mutations of ASXL1 gene in myeloproliferative neoplasms.

Authors:  N Carbuccia; A Murati; V Trouplin; M Brecqueville; J Adélaïde; J Rey; W Vainchenker; O A Bernard; M Chaffanet; N Vey; D Birnbaum; M J Mozziconacci
Journal:  Leukemia       Date:  2009-07-16       Impact factor: 11.528

2.  Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.

Authors:  Johanna Flach; Frank Dicker; Susanne Schnittger; Alexander Kohlmann; Torsten Haferlach; Claudia Haferlach
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

3.  Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.

Authors:  Robert Kralovics; Yongli Guan; Josef T Prchal
Journal:  Exp Hematol       Date:  2002-03       Impact factor: 3.084

4.  Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

Authors:  A Tefferi; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; M M Patnaik; C A Hanson; A Pardanani; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-19       Impact factor: 11.528

5.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

6.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

7.  Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.

Authors:  Mamta Tahiliani; Kian Peng Koh; Yinghua Shen; William A Pastor; Hozefa Bandukwala; Yevgeny Brudno; Suneet Agarwal; Lakshminarayan M Iyer; David R Liu; L Aravind; Anjana Rao
Journal:  Science       Date:  2009-04-16       Impact factor: 47.728

8.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

9.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

10.  Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

Authors:  Azim M Mohamedali; Alexander E Smith; Joop Gaken; Nicholas C Lea; Syed A Mian; Nigel B Westwood; Corinna Strupp; Norbert Gattermann; Ulrich Germing; Ghulam J Mufti
Journal:  J Clin Oncol       Date:  2009-06-15       Impact factor: 44.544

View more
  9 in total

1.  Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Authors:  Sabine Jeromin; Torsten Haferlach; Sandra Weissmann; Manja Meggendorfer; Christiane Eder; Niroshan Nadarajah; Tamara Alpermann; Alexander Kohlmann; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

2.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Authors:  Michael R Savona; Luca Malcovati; Rami Komrokji; Ramon V Tiu; Tariq I Mughal; Attilio Orazi; Jean-Jacques Kiladjian; Eric Padron; Eric Solary; Raoul Tibes; Raphael Itzykson; Mario Cazzola; Ruben Mesa; Jaroslaw Maciejewski; Pierre Fenaux; Guillermo Garcia-Manero; Aaron Gerds; Guillermo Sanz; Charlotte M Niemeyer; Francisco Cervantes; Ulrich Germing; Nicholas C P Cross; Alan F List
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

3.  Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

Authors:  O Abdel-Wahab; A Pardanani; J Patel; M Wadleigh; T Lasho; A Heguy; M Beran; D G Gilliland; R L Levine; A Tefferi
Journal:  Leukemia       Date:  2011-04-01       Impact factor: 11.528

Review 4.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388

5.  Alterations of 5-hydroxymethylcytosine in human cancers.

Authors:  Christopher J Mariani; Jozef Madzo; Erika L Moen; Ali Yesilkanal; Lucy A Godley
Journal:  Cancers (Basel)       Date:  2013-06-25       Impact factor: 6.639

Review 6.  The emerging insights into catalytic or non-catalytic roles of TET proteins in tumors and neural development.

Authors:  Hao Lian; Wen-Bin Li; Wei-Lin Jin
Journal:  Oncotarget       Date:  2016-09-27

7.  TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.

Authors:  Andrea Patriarca; Donatella Colaizzo; Gianluca Tiscia; Raffaele Spadano; Silvia Di Zacomo; Antonio Spadano; Ida Villanova; Maurizio Margaglione; Elvira Grandone; Alfredo Dragani
Journal:  Biomed Res Int       Date:  2013-05-25       Impact factor: 3.411

Review 8.  Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.

Authors:  Andrew L Sochacki; Melissa A Fischer; Michael R Savona
Journal:  Onco Targets Ther       Date:  2016-04-15       Impact factor: 4.147

9.  Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion.

Authors:  C Christofer Juhlin; Sylvia L Asa; Kenbugul Jatta; Homeyra Naserhojati Rodsari; Ivan Shabo; Felix Haglund; Brett Delahunt; Hemamali Samaratunga; Lars Egevad; Anders Höög; Jan Zedenius
Journal:  Head Neck Pathol       Date:  2020-06-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.